Androgen receptor CAG repeat length and risk of biliary tract cancer and stones

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 3, 2010, Pages 787-793

  Meyer, Tamra E ^a   O'Brien, Thomas G ^b   Andreotti, Gabriella ^a   Yu, Kai ^a   Li, Qizhai ^a,c   Gao, Yu Tang ^e   Rashid, Asif ^d   Shen, Ming Chang ^e   Wang, Bing Sheng ^e   Han, Tian Quan ^f   Zhang, Bai He ^g   Niwa, Shelley ^h   Fraumeni Jr , Joseph F ^a   Hsing, Ann W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c CHINESE ACADEMY OF SCIENCES   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e FUDAN UNIVERSITY   (China)

^f SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h WESTAT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BILE DUCT CANCER; CAG REPEAT; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GALLBLADDER CANCER; GALLSTONE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TRINUCLEOTIDE REPEAT;

ADULT; AGED; BILIARY TRACT NEOPLASMS; CHINA; FEMALE; GALLSTONES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; RISK FACTORS; TRINUCLEOTIDE REPEATS;

EID: 77949666173     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0973     Document Type: Article

References (39)

1. Hsing AW, Rashid A, Devesa SS, Fraumeni JF, Jr. Biliary tract cancer. In: Schottenfeld D, Fraumeni JF, Jr., editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006, p. 787-800.
2. Khan ZR, Neugut AI, Ahsan H, Chabot JA. Risk factors for biliary tract cancers. Am J Gastroenterol 1999;94:149-52.
3. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000;6:225-36.
4. Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 2007;31:26-33.
5. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003;26:76-83.
6. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22: 3181-6.
7. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002;155:883-90.
8. Lillie E, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003;5:164-73.
9. Hsing AW, Sakoda LC, Rashid A, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res 2008;68:6442-52.
10. Boorman DW, Guo Y, Visvanathan K, Helzlsouer K, O'Brien TG. Automated fragment analysis method for determining androgen receptor CAG repeat length. Biotechniques 2002;33:140-3.
11. O'Brien TG, Guo Y, Visvanathan K, et al. Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups. Mol Carcinog 2004;41:120-3.
12. Lyon MF. X-chromosome inactivation. Curr Biol 1999;9:R235-7.
13. Hsing AW, Gao Y-T, Wu G, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000; 60:5111-6.
14. Kristiansen M, Knudsen GPS, Bathum L, et al. Twin study of genetic and aging effects on X chromosome inactivation. Eur J Hum Genet 2005;13:599-606.
15. Brum IS, Spritzer PM, Paris F, Maturana MA, Audran F, Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J Soc Gynecol Investig 2005;12:135-41.
16. Ibanez L, Ong KK, Mongan N, et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003;88:3333-8.
17. Westberg L, Baghaei F, Rosmond R, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor {β} gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001; 86:2562-8.
18. Haiman CA, Brown M, Hankinson SE, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 2002;62:1045-9.
19. Hickey T, Chandy A, Norman RJ. TheaAndrogen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-5.
20. Hietala M, Sandberg T, Borg A, Olsson H, Jernstrom H. Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women. Hum Reprod 2007;22:83-91.
21. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000;85:3251-5.
22. Leo VD, Lanzetta D, Cariello PL, D'Antona D, Morgante G. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF). Clin Endocrinol 1998;49:85-9.
23. Moghetti P, Casterllo R, Negri C, et al. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril 1995;64:511-7.
24. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304-10.
25. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Mineral Res 1997;12:1833-43.
26. Ferro P, Catalano MG, Dell'Eva R, Fortunati N, Pfeffer U. The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol Cell Endocrinol 2002;193:109-20.
27. Kamat A, Hinshelwood MM, Murry BA, Mendelson CR. Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 2002;13:122-8.
28. Schwarz D, Kisselev P, Schunck W-H, et al. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenet Genomics 2000;10:519-30.
29. Park SK, Andreotti G, Sakoda LC, et al. Variants in hormone-related genes and the risk of biliary tract cancers and stones: a populationbased study in China. Carcinogenesis 2009;30:606-14.
30. Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 2007;92: 3604-10.
31. Huhtaniemi IT, Pye SR, Limer KL, et al. Increased estrogen rather than decreased androgen action Is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab 2009;94:277-84.
32. Mifsud A, Choon AT, Fang D, Yong EL. Prostate-specific antigen, testosterone, sex-hormone binding globulin and androgen receptor CAG repeat polymorphisms in subfertile and normal men. Mol Hum Reprod 2001;7:1007-13.
33. Walsh S, Zmuda JM, Cauley JA, et al. Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men. J Appl Physiol 2005;98:132-7.
34. Alevizaki M, Cimponeriu AT, Garofallaki M, et al. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol 2003;59:749-55.
35. Goutou M, Sakka C, Stakias N, Stefanidis I, Koukoulis GN. AR CAG repeat length is not associated with serum gonadal steroids and lipid levels in healthy men. Int J Androl 2009;32:616-22.
36. Lapauw B, Goemaere S, Crabbe P, Kaufman JM, Ruige JB. Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? Eur J Endocrinol 2007;156:395-401.
37. Van Pottelbergh I, Lumbroso S, Goemaere S, Sultan C, Kaufman JM. Lack of influence of the androgen receptor gene CAG-repeat polymorphism on sex steroid status and bone metabolism in elderly men. Clin Endocrinol 2001;55:659-66.
38. Zitzmann M, Brune M, Kornmann B, et al. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 2001;86:4867-73.
39. Brufsky A, Fontaine-Rothe P, Berlane K, et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997;49:913-20.